HRTX Logo

Heron Therapeutics, Inc. (HRTX) 

NASDAQ$2.32
Market Cap
$353.41M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
622 of 924
Rank in Industry
358 of 527

HRTX Insider Trading Activity

HRTX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$00–
Sells
$00–

Related Transactions

No records found

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or â€¦

Insider Activity of Heron Therapeutics, Inc.

Over the last 12 months, insiders at Heron Therapeutics, Inc. have bought $0 and sold $0 worth of Heron Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Heron Therapeutics, Inc. have bought $3.69M and sold $187,403 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 25,000 shares for transaction amount of $27,250 was made by Forbes William P (EVP, Chief Development Officer) on 2023‑11‑17.

List of Insider Buy and Sell Transactions, Heron Therapeutics, Inc.

2023-11-17PurchaseForbes William PEVP, Chief Development Officer
25,000
0.0179%
$1.09$27,250+121.10%
2023-11-16PurchaseCollard Craig AChief Executive Officer
150,000
0.1065%
$0.92$137,970+162.87%
2023-11-16PurchaseDuarte IraEVP, Chief Financial Officer
85,000
0.0584%
$0.89$75,599+162.87%
2023-11-16PurchaseForbes William PEVP, Chief Development Officer
50,000
0.0363%
$0.94$46,995+162.87%
2023-07-21PurchaseMorgan Adamdirector
2.49M
2.0703%
$1.37$3.41M+61.59%
2022-05-03SaleMANHARD KIMBERLYEVP, Drug Development
1,504
0.0015%
$4.76$7,154-38.95%
2021-12-21SaleChristian Waagedirector
300
0.0003%
$9.73$2,920-56.73%
2021-12-21SaleJohnson Craig Adirector
250
0.0002%
$9.73$2,432-56.73%
2021-09-21SaleChristian Waagedirector
600
0.0006%
$12.31$7,384-54.08%
2021-09-21SaleJohnson Craig Adirector
500
0.0005%
$12.30$6,148-54.08%
2021-06-21SaleChristian Waagedirector
600
0.0006%
$15.20$9,118-40.10%
2021-06-21SaleJohnson Craig Adirector
500
0.0005%
$15.20$7,601-40.10%
2021-05-03SaleMANHARD KIMBERLYEVP, Drug Development
3,058
0.0032%
$17.66$54,017-39.34%
2021-04-15SaleChristian Waagedirector
600
0.0006%
$17.51$10,508-38.97%
2021-04-06SaleJohnson Craig Adirector
500
0.0005%
$17.22$8,610-33.90%
2021-01-14SaleSzekeres David LeslieEVP, Chief Operating Officer
1,654
0.0018%
$18.09$29,920-29.12%
2021-01-08SaleSzekeres David LeslieEVP, Chief Operating Officer
7,142
0.0039%
$9.83$70,219-32.19%
2020-12-22SaleMANHARD KIMBERLYEVP, Drug Development
20,000
0.0176%
$16.50$330,000-32.95%
2020-05-01SaleMANHARD KIMBERLYExecutive VP, Drug Development
2,316
0.0013%
$6.98$16,176+25.16%
2019-11-29SaleMANHARD KIMBERLYExecutive VP, Drug Development
48,000
0.0274%
$13.00$624,000-35.68%
Total: 115

Insider Historical Profitability

18.13%
Morgan Adamdirector
6986744
4.5866%
$16.21M10+61.59%
TANG KEVIN Cdirector
5799810
3.8074%
$13.46M191+4.62%
Collard Craig AChief Executive Officer
186496
0.1224%
$432,670.7210+162.87%
RIEPENHAUSEN PETERdirector
179332
0.1177%
$416,050.2420
Quart Barry DChief Executive Officer
94652
0.0621%
$219,592.6434<0.0001%

Historical Insider Profitability vs. Competitors

$5,911,307
70
-1.38%
$309.77M
Heron Therapeutics, Inc.
(HRTX)
$109,415,500
33
18.13%
$353.41M
$41,446,394
27
12.91%
$340.18M
$14,865,077
18
-28.56%
$389.16M
$49,750,490
17
37.19%
$307.1M

HRTX Institutional Investors: Active Positions

Increased Positions69+31.94%8M+6.9%
Decreased Positions86-39.81%15M-12.45%
New Positions25New5MNew
Sold Out Positions37Sold Out6MSold Out
Total Postitions199-7.87%115M-5.54%

HRTX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Rubric Capital Management Lp$65,982.0017.58%26.71M00%2024-12-31
Blackrock, Inc.$21,219.005.65%8.59M+56,175+0.66%2024-12-31
Adage Capital Partners Gp, L.L.C.$20,995.005.59%8.5M-350,000-3.96%2024-12-31
Vanguard Group Inc$20,149.005.37%8.16M-562,567-6.45%2024-12-31
Velan Capital Investment Management Lp$17,257.004.6%6.99M00%2024-12-31
Tejara Capital Ltd$11,514.003.07%4.66M-644,269-12.14%2024-12-31
Palisade Capital Management, Lp$9,698.002.58%3.93M-65,889-1.65%2024-12-31
D. E. Shaw & Co., Inc.$9,198.002.45%3.72M-660,971-15.07%2024-12-31
State Street Corp$7,771.002.07%3.15M-46,243-1.45%2024-12-31
Point72 Asset Management, L.P.$7,597.002.02%3.08M+3MNew2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.